MedWatch

Novo Holdings raises stakes on Zealand Pharma competitor – joins million-dollar investment

Once again, Novo Ventures posts millions of dollars in newly founded spinout company Vectivbio, which is developing a treatment for short bowel syndrome. This time, the Danish venture fund joins a USD 110m investment in the firm, which plans to challenge Zealand Pharma with its drug.

Partner at Novo Ventures Naveed Siddiqi | Foto: Novo Holdings / PR

Recently founded spinout company Vectivbio has landed a USD 110m investment from both existing investors and newcomers.

Amongst the former are Novo Ventures, which joined a consortium of major investors that posted DKK 235m (USD 37.2m) into Vectivbio at the start of the year, after having developed a liking for the firm and its drug apraglutide, which has recently showed promising results during phase II trials for treating short bowel syndrome.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier